Wealth Advisors of Tampa Bay LLC Has $660,000 Holdings in DexCom, Inc. $DXCM

Wealth Advisors of Tampa Bay LLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 62.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,810 shares of the medical device company’s stock after selling 16,415 shares during the period. Wealth Advisors of Tampa Bay LLC’s holdings in DexCom were worth $660,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Twin Peaks Wealth Advisors LLC bought a new position in DexCom in the second quarter worth $26,000. SJS Investment Consulting Inc. increased its holdings in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the period. Financial Consulate Inc. bought a new stake in DexCom in the 3rd quarter valued at $29,000. Sound Income Strategies LLC raised its stake in shares of DexCom by 83.8% in the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after buying an additional 285 shares in the last quarter. Finally, Rothschild Investment LLC lifted its holdings in shares of DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after acquiring an additional 245 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ:DXCM opened at $64.24 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The firm has a market cap of $24.72 billion, a PE ratio of 30.59, a price-to-earnings-growth ratio of 1.27 and a beta of 1.48. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company’s 50-day moving average price is $70.66 and its two-hundred day moving average price is $68.45.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 earnings per share. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Robert W. Baird set a $87.00 target price on shares of DexCom in a research report on Friday, February 13th. Citigroup raised their price target on shares of DexCom from $77.00 to $84.00 and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the company a “buy” rating in a report on Friday, February 13th. Truist Financial reiterated a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Finally, Wells Fargo & Company dropped their target price on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $85.50.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.